Mesenchymal stem cells in the treatment of osteonecrosis of the jaw
10.5125/jkaoms.2021.47.2.65
- Author:
Gianfilippo NIFOSÌ
1
;
Lorenzo NIFOSÌ
;
Antonio Fabrizio NIFOSÌ
Author Information
1. Department of Oncology and Hematology, VSHA Fondation , Passy, French.
- Publication Type:REVIEW ARTICLE
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2021;47(2):65-75
- CountryRepublic of Korea
- Language:English
-
Abstract:
Medication-related osteonecrosis of the jaw (MRONJ) has recently associated to the increase in antiresorptive and anti-angiogenic drugs prescriptions in the treatment of oncologic and osteoporotic patients. The physiopathogenesis of MRONJ remains unclear and available treatments are unsatisfactory.Newer pharmacological treatments have shown good results, but are not curative and could have major side effects. At the same time as pharmacological treatments, mesenchymal stem cells (MSCs) have emerged as a promising therapeutic modality for tissue regeneration and repair. MSCs are multipotential non-hematopoietic progenitor cells capable to differentiating into multiple lineages of the mesenchyme. Bone marrow MSCs can differentiate into osteogenic cells and display immunological properties and secrete paracrine anti-inflammatory factors in damaged tissues. The immunomodulatory, reparative, and anti-inflammatory properties of bone marrow MSCs have been tested in a variety of animal models of MRONJ and applied in specific clinical settings. The aim of this review is to discuss critically the immunogenicity and immunomodulatory properties of MSCs, both in vitro and in vivo, the possible underlying mechanisms of their effects, and their potential clinical use as modulators of immune responses in MRONJ, and to identify clinical safety and recommendations for future research.
